- Conditions
- Dry Eye
- Interventions
- HL036 Ophthalmic Solution, Placebo
- Biological
- Lead sponsor
- HanAll BioPharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Newport Beach, California • Torrance, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 454
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Eyelash Hypotrichosis, Alopecia Areata
- Interventions
- bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo), timolol ophthalmic solution 0.5%, AGN-207281 vehicle ophthalmic solution (Placebo)
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Atopic Dermatitis
- Interventions
- ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle
- Drug
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 29 more
- Conditions
- Mydriasis, Dilation
- Interventions
- Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
- Drug · Other
- Lead sponsor
- Opus Genetics, Inc
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 4
- States / cities
- Pittsburg, Kansas • Lexington, Kentucky • Athens, Ohio + 1 more
- Conditions
- Atopic Dermatitis
- Interventions
- ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
- Drug · Other
- Lead sponsor
- Opus Genetics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 5
- States / cities
- Mission Hills, California • Morrow, Georgia • Ann Arbor, Michigan + 2 more
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- AL-37807 ophthalmic suspension, 0.1%, Timolol gel forming solution, 0.5%, AL-37807 ophthalmic solution vehicle, Latanoprost ophthalmic solution
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Presbyopia
- Interventions
- AGN-199201, AGN-190584, AGN-199201 Vehicle
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 40 Years to 55 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Osteoarthritis, Knee
- Interventions
- Capsaicin Topical Solution, Drug product vehicle
- Drug · Other
- Lead sponsor
- Propella Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- Clearwater, Florida • Tampa, Florida • Dallas, Texas
- Conditions
- Onychomycosis of Toenails
- Interventions
- AN2690 Topical Solution, 5%, Solution Vehicle
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Hot Springs, Arkansas • Burbank, California + 23 more
- Conditions
- Dry Eye Disease
- Interventions
- SY-201 Ophthalmic Solution 2.0%, SY-201 Ophthalmic Solution 1.0%, SY-201 Ophthalmic Solution 0.5%, SY-201 Ophthalmic Solution Vehicle
- Drug
- Lead sponsor
- Seinda Pharmaceutical Guangzhou Corporation
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Ocular Redness
- Interventions
- Placebo, Brimonidine tartrate 0.025%
- Drug
- Lead sponsor
- Eye Therapies, LLC
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- IgA Nephropathy
- Interventions
- OMS721, Vehicle (D5W or saline)
- Biological · Other
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 34
- States / cities
- Florence, Alabama • Mesa, Arizona • Phoenix, Arizona + 29 more
- Conditions
- Hypotrichosis
- Interventions
- Bimatoprost 0.03% solution, Vehicle solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
- Interventions
- PBA-0405
- Drug
- Lead sponsor
- Pure Biologics S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Shreveport, Louisiana • Portland, Oregon • Philadelphia, Pennsylvania + 1 more
- Conditions
- Postherpetic Neuralgia
- Interventions
- Civamide Nasal Spray, Placebo
- Drug
- Lead sponsor
- Winston Laboratories
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Lauderdale Lakes, Florida • Tampa, Florida + 2 more
- Conditions
- Dry Eye Syndrome
- Interventions
- Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle)
- Drug
- Lead sponsor
- Mitotech, SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Newport Beach, California • Louisville, Kentucky + 4 more
- Conditions
- Subcutaneous Fat Disorder
- Interventions
- 10XB-101 Solution for Injection, 6.0%, Placebo Solution for Injection (no active ingredient)
- Drug
- Lead sponsor
- 10xBio, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Rolling Meadows, Illinois • New Brighton, Minnesota
- Conditions
- Hyperemia
- Interventions
- Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 507 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 1 more
- Conditions
- Presbyopia
- Interventions
- 0.75% phentolamine ophthalmic solution, Placebo
- Drug
- Lead sponsor
- Opus Genetics, Inc
- Industry
- Eligibility
- 45 Years to 64 Years
- Enrollment
- 569 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 39
- States / cities
- Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 32 more
- Conditions
- Non-infectious Anterior Uveitis
- Interventions
- ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic Solution
- Drug
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 24 more
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- 1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
- Drug
- Lead sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky • Nashville, Tennessee
- Conditions
- Persistent Corneal Epithelial Defect
- Interventions
- Cenegermin, Vehicle
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 18
- States / cities
- Huntington Beach, California • Laguna Hills, California • Loma Linda, California + 14 more